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was reduced to 22 items. Exploratory and confirmatory factor analysis identified 21 
items contributing to 3 hypoglycemia domains (Symptoms [8 items], Compensatory 
Behaviors [7 items], Worry [6 items]) and a single-item of global symptom awareness. 
HPQ domains had high internal consistency reliability (Cronbach’s alpha= 0.78-0.92). 
Construct validity was demonstrated by significant correlations between HPQ scores 
with HRQoL, treatment satisfaction, and health status. HPQ also demonstrated abil-
ity to discriminate between known groups. Compensatory behaviors and symptom 
awareness were higher for patients with a recent low blood sugar event (p< 0.001) 
and high symptom awareness corresponded to less concern about experiencing 
symptoms of low blood sugar and worry (p< 0.05). ConClusions: These results 
provide preliminary evidence that HPQ is reliable and valid for assessing the experi-
ence and impact of hypoglycemia on T2DM patients.
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objeCtives: To test the reliability and validity and of newly translated Hindi version 
of DQOL-M instrument in Indian type 2 diabetic populations. Methods: Backward 
and forward translation was carried out and intermediate version was compared 
with original instrument to check the linguistic equivalence. After pilot testing the 
final Hindi version of DQOL-M was administered to 250 patients with type 2 dia-
betes twice at the interval of four weeks. Psychometric parameters like treatment 
satisfaction, Impact of treatment, worries of social vocational issues of diabetes 
were assessed. Cronbach alpha for total score was calculated to study the reliability 
of instrument. Results: Internal consistency was assessed using Cronbach alpha 
and value of 0.86 was gained for the summary score. Cronbach alpha for treatment 
satisfaction was found to be 0.77, for Impact of treatment it was 0.73 and for wor-
ries of social vocational issues score of 0.83 was gained. No significant difference 
was observed in test-retest analysis. Pearson correlations were assessed for all the 
four subscales and were found to be significant. ConClusions: This modified 
and final translated version of instrument confirms the linguistic validity of the 
questionnaire for the Hindi language and evaluates the psychometric properties 
of the questionnaire for psychometric validation. Indian Hindi version of DQOL-M 
is valid and reliable instrument for measuring HRQOL of diabetic type 2 patients.
DiaBeTes/enDocrine DisorDers – Health care use & Policy studies
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objeCtives: Metabolic agents have the highest expense (130 million Euros per year 
in the Valencian Community) among the top five therapeutic categories of drugs 
for adults aged 18 and over. Treatment of Diabetes Mellitus (DM) is the main cause 
of this. Moreover, diabetes is a chronic illness that requires continuous medical 
care and patient self-management education to prevent acute complications and 
to reduce the risk of long-term complications. Clinical Risk Groups (CRGs) are a 
tool claimed as valid for diabetes patient management. In this context we use this 
methodology to conduct a pharmaceutical cost analysis of diabetes in an Eastern 
Spanish region where the prevalence reaches approximately 8 %. Methods: A 
database of 5,200,000 subjects was used to analyse the prevalence of patients with 
DM, comorbidity and complications. The patients with DM diagnoses were clas-
sified into CRGs to know their severity levels and pharmaceutical cost was also 
assigned. A multivariable statistical analysis was performed to evaluate the cor-
relation and level of explanation between CRGs’ severity level and pharmaceutical 
expenditure. Results: Identified 300,698 patients with DM type 2 for a prevalence 
of 7.85% in men and 6.77% in women being the 13.2% and 7,98% in unders 50 years 
old, respectively. The 69,1% treated with orals hypoglycemics being combied therapy 
in over 75% of these. The use cosumption ratio glucometer strip, increaes with 
disease progression. It Was posible to identify the presence of complicactions in 
patiens analysed. A high correlation between pharmaceutical costs and CRG severity 
level was found. Comorbidity is a predictor for adjusting the risk of pharmaceuti-
cal expenditure. ConClusions: The model obtained could be a useful tool for 
managing pharmaceutical budget policies and patient management. The use of 
this measurement technique is useful for monitoring the health medical expense.
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objeCtives: To assess the improvement in knowledge and attitude of Pharmacy stu-
dent towards diabetes by implementing one week education program. Methods: 
Study was conducted between January 7, 2013 to January 11, 2013 which engaged 
pharmacy students comprising two groups: experimental and control groups. 
Lectures and visual presentations on diabetic education and practice were con-
ducted. Three surveys were performed on two group’s i.e. non intervened control, 
non- intervened experimental and intervened experimental surveys. Questionnaire 
was used as survey tool. Results: Mean score on knowledge about diabetes was 
increased from 68.81% to 88.90% after educational intervention while that of control 
group was 74.75%. General knowledge of diabetes was increased from 66.37% to 
89.90% while that of control was 69.28%. Risk factors knowledge was increased from 
61.05% to 90.20% while that of control was 70.20%. Symptoms knowledge increased 
debido a la DM se estimó en $21,516 ± 8062 año/persona. ConClusiones: La DM 
afecta significativamente la productividad laboral en nuestro medio.
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cosTo Del auToMoniToreo glucéMico en PacienTes en TraTaMienTo 
coMBinaDo oral y con insulina en argenTina
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objeCtivos: Aunque el automonitoreo glucémico (AMG) es una herramienta útil 
para optimizar el control de la diabetes, no existe en Argentina evidencia de su uso 
e impacto económico. Este estudio trata de estimar en Argentina, el número de tiras 
reactivas (TR) para AMG utilizadas en el Sistema de la Seguridad Social (SSS) y su 
impacto en el costo total de la prescripción terapéutica, en la transición de terapia 
combinada de antidiabéticos orales (ADO) al agregado de insulina. MetodologíAs: 
Estudio observacional retrospectivo, utilizando registros de una organización del SSS 
(OSPERYH, consumo de TR de 681 afiliados durante 2012) y de otras dos entidades 
de la SSS, a través de 8.115 recetas anónimas de medicamentos y TR prescriptas 
en el período Febrero-Abril 2012 y registradas por el Colegio Farmacéutico de la 
Provincia de Buenos Aires (COLFARMA). Los resultados representan la media ± des-
vío estándar (DS) o proporciones. Evaluación estadística: utilizamos los test t de 
student, Kruskal-Wallis y Chi cuadrado, según correspondiera. Se consideraron sig-
nificativas diferencias con p< 0,05. ResultAdos: OSPERYH: las TR fueron provistas 
bajo sistema de auditoría que incluye educación diabetológica, tipo de tratamiento y 
grado de control metabólico. Los tipos de tratamiento afectaron significativamente 
el consumo mensual de TR: combinación ADOs 25±12 vs. , ADO+insulina 36±15. El 
costo total combinación ADOs fué $456 vs.ADO+insulina $669 y las TR represen-
taron el 42% y 32% del costo total, respectivamente. COLFARMA: también el tipo de 
terapia afectó significativamente el consumo mensual de TR pero con valores tres 
veces superiores: combinación ADOs 75±47 vs. ADO+insulina 89±63. El costo total 
combinación ADOs fue $711 vs.ADO+insulina $983, y las TR representaron el 63% y 
54% del costo total, respectivamente. ConClusiones: El consumo de TR para AMG 
aumenta en función de la incorporación de insulina al tratamiento y auditorías 
como la descripta optimizan su consumo e impacto económico.
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objeCtivos: Evaluar la relación entre el Indice de Masa Corporal (IMC) y el gasto 
en medicamentos de personas con Diabetes (DM) en Argentina. MetodologíAs: 
Estudio descriptivo observacional relevando el IMC y el consumo de medicamentos 
de la Base QUALIDIAB. El gasto mensual en medicamentos se determinó mediante 
técnicas de microcosteo, considerándose el precio promedio de las presentaciones 
disponibles en el mercado, sin ajustes. Los valores se expresaron en pesos argen-
tinos (Diciembre 2012). Las personas se estratificaron según IMC de acuerdo a la 
clasificación de la OMS (Normal: ≥ 18,5 y < 25; Sobrepeso: ≥ 25 y < 30; Obesidad: 
IMC≥ 30). Los resultados se expresaron como media ± desvío estándar (DS). Para las 
comparaciones se utilizaron los test t de student, ANOVA y Kruskal-Wallis, según 
correspondiera. Coeficientes de correlación de Pearson (r) se utilizaron para evaluar 
el grado de asociación. Se consideraron significativos p< 0,05. ResultAdos: Se anal-
izaron 1134 registros, edad 63 ± 12 años, 55,4% mujeres. El gasto promedio mensual 
en medicamentos fue de $ 975, el gasto en medicamentos para la DM fue $779, 
para la Hipertensión $ 241 y para la Dislipemia $ 128. El gasto en medicamentos 
aumentó en función del IMC: Normal: $782; Sobrepeso: $936 y Obesidad: $1149. 
El gasto fue significativamente mayor en Hombres ($1045 vs. $919). El gasto total 
de medicamentos se correlacionó significativamente con IMC (r: 0,164), al igual 
que el correspondiente a medicamentos antihipertensivos (r: 0,113) y los utiliza-
dos para controlar la hiperglucemia (r: 0,079). ConClusiones: En pacientes con 
DM en Argentina, el IMC se asocia positivamente con el gasto en medicamentos. 
Estrategias terapéuticas que disminuyan efectivamente el IMC generarían beneficios 
tanto médicos como económicos.
DiaBeTes/enDocrine DisorDers – Patient-reported outcomes & Patient 
Preference studies
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objeCtives: The Hypoglycemia Perspectives Questionnaire (HPQ) was developed 
with clinician and patient input to assess symptoms, behaviors, and impact of 
hypoglycemia on diabetic patients. Methods: The HPQ was administered to adult 
patients with type 2 diabetes mellitus (T2DM) on antidiabetic treatment as part 
of a cross-sectional, epidemiological study evaluating hypoglycemia and health-
related quality of life (HRQoL) in Cyprus. Demographic and clinical data were col-
lected. Patients also completed the Audit of Diabetes Dependent Quality of Life 
(ADDQoL-19), treatment satisfaction questionnaire, and EuroQol-5 Dimensions (EQ-
5D). The original HPQ consisted of 45 items rating current status or behavior related 
to hypoglycemia on an 11-point numeric rating scale (NRS) and 7 additional descrip-
tive hypoglycemia event frequency items. Analyses included examination of HPQ 
item performance, item reduction, and factor structure. Measurement properties 
(reliability, construct validity, known-groups validity) of the final HPQ were evalu-
ated. Results: A total of 500 T2DM patients completed the HPQ with a mean age 
of 61±10 years; 32.6% women. Based on item evaluation, the original HPQ item pool 
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this study was to evaluate the cost-effectiveness of adding TVR to PR in treatment 
naive and previously treated patients with HCV in Argentina compared to PR alone 
and with the addition of BOC. Methods: A lifetime Markov model was developed 
including HCV, cirrhosis, liver transplant and death as health states. QALYs as an 
outcome measure, a private health subsector perspective and a 5% discount rate for 
health benefits and costs have been used. Costs are expressed in local currency. A 
review of the literature to obtain epidemiologic and resources utilization data was 
performed and when data were not available or validation was needed a Delphi 
panel with local experts was carried out. Deterministic and probabilistic sensitivity 
analysis was performed. Results: In comparison with PR, TVR avoided 166 cirrho-
sis cases and 13 deaths per 1,000 patients and shown an ICER of $141,922/QALY and 
$74,332/QALY for the naïve and for the previously treated patients respectively. TVR 
presented extended dominance (lower ICER) against BOC in naïve patients and com-
plete dominance (less costly and more efficacious) in most of the previously treated 
ones, except in the partial responders subgroup. Against the WHO criteria TVP ver-
sus PR presented a 42% of probability of being cost effective for naïve and 75% of 
probability of being cost effective for previously treated patients. ConClusions: 
TVR dominated BOC and its ICER against double therapy was slightly above WHO 
3x GDP criteria in Argentina from a private subsector perspective.
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objeCtivos: Evaluar la costo efectividad del uso de ácido gadotérico en reso-
nancia magnética para pacientes con insuficiencia renal crónica tipo 4 y 5, ver-
sus otros medios de contraste gadolínicos (gadopentetato de dimeglumina, 
gadoversetamida, gadodiamida, gadobutrol) analizando como desenlace la sobre-
vida del paciente que presenta como evento adverso Fibrosis Sistémica Nefrogénica 
(FSN). MetodologíAs: La efectividad de medios de contraste ha sido evaluada en 
términos de seguridad. Al revisar la literatura se encontraron diferencias en la proba-
bilidad de desarrollo (FSN) como principal complicación del uso de estos medios de 
contraste en pacientes con enfermedad renal avanzada, siendo letal en más del 56% 
de los casos. Mediante un modelo de árbol de decisión desde la perspectiva del tercero 
pagador se compararon los diferentes medios de contraste tomando como desenlace 
de análisis la sobrevida medida en años de vida ganados, para una esperanza de vida 
de 64,5 años y una edad promedio de 60 años, sobre las características del caso base. 
Los costos fueron obtenidos de precios de mercado de bases de datos de aseguradoras 
en pesos colombianos, 2012. El costo usado para las tecnologías fue el de la presen-
tación 15 ml. ResultAdos: No se encontraron reportes de casos de FSN con gado-
térico o gadobutrol. El ácido gadotérico mostró un promedio de año de vida de 1,706 
mejor que gadodiamida, gadopentetato de dimeglumina y gadoversetamida; y fue 
el menos costoso frente a todos los analizados (COP$ 132.000) seguido de Gadobutrol 
(COP$ 161.202) siendo dominante en todos los escenarios analizados. En el análisis 
tipo Montecarlo con variaciones de +/-50% mantiene su dominancia en el 95% de las 
iteraciones. ConClusiones: El acido gadotérico es la opción más favorable por su 
dominancia dada por su menor costo, y mejor o igual efectividad frente a los demás 
comparadores, justificando con esta información su mayor preferencia en el uso.
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objeCtives: The inflammatory bowel diseases (IBD) are characterized by chronic 
inflammation of the gastrointestinal tract; the irritable bowel syndrome (IBS) is a func-
tional disorder (prevalence 10%-20%). They present overlapping symptoms, making 
diagnosis difficult in primary care. Endoscopy is the gold standard for IBD, but it often 
turns negative due to IBD’s low prevalence, it is expensive, uncomfortable and risky 
for the patient. F-Calprotectin is a marker of intestine inflammation: as IBD patients 
exhibit levels higher than the general population and IBS patients, F-Calprotectin can 
be used to rule out IBD. The only CE evaluation on F-Calprotectin has been published 
by NHS (CEP09041, 2010); based on new evidence, we propose a refined model to evalu-
ate the CE of F-Calprotectin compared to the standard pre-endoscopic serologic test 
(CRP+ESR) to distinguish IBD from IBS in the UK and Brazil. Methods: F-Calprotectin 
sensitivity (0.96) and specificity (0.96) were evaluated from a meta-analysis performed 
in March 2013; CRP+ESR sensitivity (0.35) and specificity (0.73), and the costs come 
from CEP09041. Published HRQoL values for IBD and IBS were transformed in QALYs 
with transfer-to-utility techniques. The outcomes included cost savings, cost per 
QALY. Uncertainty was addressed with a probabilistic sensitivity analysis. Results: 
Results for UK show that F-Calprotectin is CE with respect to CRP+ESR: a) it results 
in more corrected IBD diagnoses at a lower price (it costs 113£ less per patient); b) it 
reduces the number of unnecessary endoscopies, increasing the number of correctly 
diagnosed IBD (N= 59) and IBS (N= 195) patients; c) it brings about a QALY gain per 
patient equal to 0.0034QALYs; the ICER of the CRP+ESR diagnostic strategy is 47,783£, 
and it falls well outside the cost-effectiveness bounds (20,000–30,000£ per additional 
QALY). Similar results were found for Brazil. ConClusions: F-Calprotectin is CE to 
rule out IBD in primary care in UK and Brazil.
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from 80.70% to 95.58% while that of control was 88.56%. Therapeutic complications 
knowledge was increased from 71.58% to 88.57% while that of control was 78.82%. 
Medication knowledge of diabetes was increased from 80.26% to 83.67% while that 
of control was 74.51%. Lifestyle knowledge of diabetes was increased from 72.81% to 
89.80% while that of control was 84.64%. Knowledge about preventions in diabetes 
was increased from 69.47% to 86.53% while that of control was 80.78%. Knowledge 
about diet was increased from 48.68% to 77.55% while that of control was 42.16%. 
Knowledge about monitoring diabetic conditions was increased from 84.21% to 
92.35% while that of control was 86.27. Scores in all diabetic knowledge aspect 
was increased after education intervention and was significantly (P< 0.05) different 
from that of control group. ConClusions: Institutions may ethically help in the 
reinforcement of student’s knowledge by implementing such educational programs 
which may increase the educational skills, efficiency and confidence of pharmacy 
students as well as professionals.
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acuTe exPosure of BisPHenol-a froM elecTronic gaDgeTs Does noT 
inDuce oxiDaTiVe sTress in THe raT Brain
Kumar N.1, Sharma V.P.2
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objeCtives: To investigate the effects of BPA on oxidative damage in terms of activ-
ity level of antioxidant enzymes in different regions of the rat brain. Methods: 
In this study, BPA migration was estimated through physio-chemical parameters 
and leachate (equivalent to 4mg/kg body weight) was used for animal dosing. 
Three groups of Albino Wister rats (190+20grm) were used for control, sham, and 
treated. The antioxidant enzymes including superoxide dismutase (Mn-SOD), cata-
lase (CAT), glutathione peroxidase (GPx) and reduced glutathione level (GSH) were 
measured in different brain regions i.e. corpus striatum, frontal cortex, thalamus 
and midbrain. Results: No significant changes were observed in most of the 
brain regions yet the level of GPx activity in corpus striatum (29.65±0.98 nmoles/
min/mg protein) and level of GSH activity in frontal cortex (2.33±0.12 µmoles/g 
protein) was found to decrease significantly (p< 0.05) when compared to controls. 
In addition, no significant effects were observed for the oxidative damage in brain 
regions of sham group when compared to control group. ConClusions: Thus 
study suggests that acute exposure (4mg/kg body weight per day up to 28 days) of 
BPA does not induce significant oxidative damage in the rat brain. Furthermore, 
study might re-examine before affirm the final remark for subscribers and regula-
tory bodies at similar doses.
gasTroinTesTinal DisorDers – clinical outcomes studies
Pgi1
cosTs of PriMary Biliary cirrHosis TreaTMenT WiTH ursoDeoxycHolic 
aciD in Brazil
Lemos L.L.P., Mata A.D., Gomes R.M., Guerra Junior A.A., Acurcio F.A.
Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
objeCtives: To estimate the cost of treatment of primary biliary cirrhosis with 
ursodeoxycholic acid (UDCA) in Brazil and to evaluate the efficacy and safety of 
this treatment. Methods: We considered the doses of 8, 12 and 15mg/Kg and 
a patient weighing 70Kg to estimate the cost of treatment. We used the maxi-
mum price to the producer in the CMED (Drug Market Regulation Chamber) list 
of 03/15/2013 with 18% of ICMS (Circulating Goods and Services Tax), and applied 
CAP (Adequacy Coefficient of Prices)of 25% . We used Purchasing Power Parity 
of 1,0USD= 1,8BRL. To access efficacy and safety we searched the databases The 
Cochrane Library, CDR, Tripdatabase, MEDLINE and LILACS to identify systematic 
reviews (SR) of clinical trials that reported data on mortality, biochemical improve-
ment measurements and adverse events. Results: The estimated annual cost of 
treatment was USD2,239.24 with the dose of 8mg/Kg; USD3,168.97with the dose 
of 12mg/Kg; and UDS4,098.71 with the dose of 15mg/Kg. We included seven SRs; 
four evaluating UDCA versus placebo/observation; one UDCA versus colchicine; 
one UDCA versus methotrexate; and one UDCA versus bezafibrate. Generally, until 
four years of treatment there were no difference between UDCA and placebo/other 
interventions with respect with mortality, hepatic transplant incidence, wors-
ening or arising of itching and fatigue, and incidence of hepatic complications. 
In the other hand there were improvements in surrogate outcomes like hepatic 
function markers, especially bilirubin. In all studies UDCA was well tolerated by 
patients. ConClusions: Improvements in the blood levels of hepatic markers 
did not match mortality rates or the incidence of transplant. The main symptoms 
of the disease, itching or fatigue, were not altered by the use of UDCA. There is a 
lack of evidence of studies evaluating quality of life of the patients, which perhaps 
could be improved by the use of UDCA. Besides, long observational studies could 
connect biochemical improvement and mortality rate.
gasTroinTesTinal DisorDers – cost studies
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objeCtives: Direct acting antiviral therapies (DAA) in addition to PEG 2a + RBV (PR) 
are a new therapeutic option with higher rates of sustained virological response 
(SVR) than dual therapy (PR) alone in chronic hepatitis C. Currently, two alternatives 
of DAA, telaprevir (TVR) and boceprevir (BOC), are available in Argentina. The aim of 
